NEWS HIGHLIGHTSMedia Articles Related to Ceprotin (Protein C)
DVT (Deep Vein Thrombosis) and Pulmonary Embolism (PE) Quiz
Source: MedicineNet Deep Vein Thrombosis Specialty [2017.09.20]
Title: DVT (Deep Vein Thrombosis) and Pulmonary Embolism (PE) Quiz
Category: MedicineNet Quiz
Created: 7/31/2014 12:00:00 AM
Last Editorial Review: 9/20/2017 1:12:43 PM
Deep Vein Thrombosis (DVT, Blood Clot in the Legs)
Source: MedicineNet Antiphospholipid Syndrome Specialty [2017.07.03]
Title: Deep Vein Thrombosis (DVT, Blood Clot in the Legs)
Category: Diseases and Conditions
Created: 2/15/2000 12:00:00 AM
Last Editorial Review: 7/3/2017 12:00:00 AM
Deep Vein Thrombosis (DVT)
Source: MedicineNet Deep Vein Thrombosis Specialty [2017.05.22]
Title: Deep Vein Thrombosis (DVT)
Category: Symptoms and Signs
Created: 2/26/2015 12:00:00 AM
Last Editorial Review: 5/22/2017 12:00:00 AM
Published Studies Related to Ceprotin (Protein C)
Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. [2011.09]
Chronic wounds arising from orthopedic surgery present a major clinical challenge. Osteomyelitis may develop from polymicrobial infection, which can be unresponsive to treatment and lead to amputation...
A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. [2011.08]
OBJECTIVE: To investigate the association between markers of acute endothelial glycocalyx degradation, inflammation, coagulopathy, and mortality after trauma. BACKGROUND: Hyperinflammation and acute coagulopathy of trauma predict increased mortality. High catecholamine levels can directly damage the endothelium and may be associated with enhanced endothelial glycocalyx degradation, evidenced by high circulating syndecan-1... CONCLUSIONS: In trauma patients, high circulating syndecan-1, a marker of endothelial glycocalyx degradation, is associated with inflammation, coagulopathy and increased mortality.
Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. [2011.04.15]
RATIONALE: Patients with acute lung injury have impaired function of the lung surfactant system. Prior clinical trials have shown that treatment with exogenous recombinant surfactant protein C (rSP-C)-based surfactant results in improvement in blood oxygenation and have suggested that treatment of patients with severe direct lung injury may decrease mortality. OBJECTIVES: Determine the clinical benefit of administering an rSP-C-based synthetic surfactant to patients with severe direct lung injury due to pneumonia or aspiration... CONCLUSIONS: In this study, rSP-C-based surfactant was of no clinical benefit to patients with severe direct lung injury. The unexpected lack of improvement in oxygenation, coupled with the results of in vitro tests, suggest that the administered suspension may have had insufficient surface activity to achieve clinical benefit.
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. [2011]
INTRODUCTION: There are no published data on the status of endogenous activated protein C (APC) in pulmonary embolism (PE), and no data on the effect of drotrecogin alfa (activated) (DAA) given in addition to therapeutic dose enoxaparin... CONCLUSIONS: In patients with acute submassive PE endogenous APC levels are low. DAA infusion enhances the inhibition of fibrin formation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00191724.
Combination of activated protein C and topical negative pressure rapidly
regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic
wounds. [2011]
Chronic wounds arising from orthopedic surgery present a major clinical
challenge. Osteomyelitis may develop from polymicrobial infection, which can be
unresponsive to treatment and lead to amputation...
Clinical Trials Related to Ceprotin (Protein C)
Ceprotin Treatment Registry [Completed]
Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock. [Recruiting]
The purpose of this study is to investigate the effects on systemic hemodynamics,
microcirculation and organ function of human Protein C concentrate in patients with sepsis
and septic shock.
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency [Completed]
The purpose of this study is to show that Protein C Concentrate is a safe and effective
treatment for subjects with congenital protein C deficiency. Depending on the type of
treatment required, patients are assigned to one of 3 study parts: Part 1 is for the
treatment of acute episodes, Part 2 is for short-term prophylaxis, and Part 3 is for
long-term prophylaxis in infants aged less than 6 months only.
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND [Completed]
This is a data collection study with the purpose of capturing dosing and treatment outcome
data in subjects with severe congenital protein C deficiency who were treated with protein C
concentrate under an Emergency Use Investigational New Drug Application (IND).
Activated Protein C and Corticosteroids for Human Septic Shock [Completed]
This study aims at comparing the efficacy and safety of recombinant human activated protein
C to that of low dose of corticosteroids and at investigating the interaction between these
drugs in the management of septic shock
|
